Peptomer Therapeutics

United Kingdom Founded: 2020 • Age: 6 yrs
Provider of drug development services for antimicrobial peptides and oligomers

About Peptomer Therapeutics

Peptomer Therapeutics is a Healthcare company based in United Kingdom founded in 2020. Provider of drug development services for antimicrobial peptides and oligomers. The company has 1 employees. Its Indian entity Peptomer Therapeutics Private Limited reported revenue of β‚Ή33.8 Lakh. Peptomer Therapeutics offers products and services including Oligomers, Peptides, and Oligomer-Peptide Hybrids. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development.

Company details

Peptomer Therapeutics provider of drug development services for antimicrobial peptides and oligomers, focusing on providing healthcare solutions, biopharma outsourcing, cdmo, small molecules peptides, drug development, and peptide. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.

Key Metrics
  • Indian entity revenue
    ₹33.8 Lakh

    FY 2024 · +58% YoY

  • Indian entity net loss
    -₹16.4 Lakh

    FY 2024 · -48% margin

  • Indian entity EBITDA
    -₹14.5 Lakh

    FY 2024 · -43% margin

  • Employee Count
    1

Products & Services of Peptomer Therapeutics

Peptomer Therapeutics offers a comprehensive portfolio of products and services, including Oligomers, Peptides, and Oligomer-Peptide Hybrids.

Oligomers
Antimicrobial Agents

Compounds effective against multi-drug resistant bacteria.

Peptides
Antimicrobial Agents

Peptidomimetics with broad-spectrum activity against pathogens.

Oligomer-Peptide Hybrids
Antimicrobial Compounds

New hybrids targeting bacteria and fungi for AMR solutions.

Board of directors of Peptomer Therapeutics Private Limited (Peptomer Therapeutics)

Peptomer Therapeutics Private Limited is the primary company behind Peptomer Therapeutics. The board of Peptomer Therapeutics Private Limited currently have 2 directors; the longest-serving is Manohar Mahato, appointed in 2020.

DirectorDesignationAppointedTenureEntity
Manohar Mahato
DIN 08606928
Director10 Jul 20206 yrs 4 moPeptomer Therapeutics Private Limited
Kantaraja Chindera
DIN 08788381
Director10 Jul 20206 yrs 4 moPeptomer Therapeutics Private Limited

Financials of Peptomer Therapeutics

Figures of Peptomer Therapeutics Private Limited, the primary company behind Peptomer Therapeutics, for FY 2024. Revenue was ₹33.8 Lakh (+58% year on year). Net loss was -₹16.4 Lakh (-48% margin). EBITDA was -₹14.5 Lakh (-43% margin).

  • ₹33.8 LakhRevenue · FY 2024 · +58% YoY
  • -₹16.4 LakhNet loss · -48% margin
  • -₹14.5 LakhEBITDA · -43% margin
  • ₹5 LakhPaid-up capital

Balance sheet, profit and loss, cash flow and ratios of Peptomer Therapeutics Private Limited are on its company page.

Premium access

Detailed financial statements for Peptomer Therapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Peptomer Therapeutics

Peptomer Therapeutics was founded in 2020.

Peptomer Therapeutics is headquartered in United Kingdom.

Peptomer Therapeutics has 1 employees.

The primary company behind Peptomer Therapeutics, Peptomer Therapeutics Private Limited, reported revenue of β‚Ή33.8 Lakh for FY 2024, up 58% year on year.

Peptomer Therapeutics provider of drug development services for antimicrobial peptides and oligomers, focusing on providing healthcare solutions, biopharma outsourcing, cdmo, small molecules peptides, drug development, and peptide. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.

Peptomer Therapeutics offers Oligomers, Peptides, and Oligomer-Peptide Hybrids.

Peptomer Therapeutics operates through Peptomer Therapeutics Private Limited.

The legal entities of Peptomer Therapeutics currently have 2 directors, including Manohar Mahato, Kantaraja Chindera.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available